New registry aims to unravel severe blood disorders in youth
NCT ID NCT03576742
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed registry study followed 80 children and young adults with severe immune cytopenias, including immune thrombocytopenia, autoimmune hemolytic anemia, and Evans syndrome. Researchers observed participants over up to 4 years to improve diagnosis and track the disease course under various treatments. No new treatments were tested; the goal was to gather data to guide future care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this registry could help doctors better diagnose and manage severe immune cytopenias in children and young adults.
- What could go wrong
- This is an observational study, not a treatment trial. It collects data only and does not test any new therapy, so direct patient benefits are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pediatric Hematology-Oncology Outpatient Clinic
Graz, Styria, 8036, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test predict clot risk in antiphospholipid syndrome?
- Can a new drug calm the immune System's attack on blood cells?
- Engineered immune cells take aim at stubborn blood disorder
- Double attack on blood disorder: could two drugs beat one for stubborn ITP?
- Cheap drug combo may tame tough anemia
- Scientists hunt for genetic roots of rare childhood blood disorder